Deregulated Gab2 Phosphorylation Mediates Aberrant AKT and STAT3 Signaling Upon PIK3R1 Loss in Ovarian Cancer

Overview

Journal Nat Commun

Specialty Biology

Date 2019 Feb 14

PMID 30755611

Citations 26

Authors

Xinran Li

Victor C Y Mak

Yuan Zhou

Chao Wang

Esther S Y Wong

Rakesh Sharma

Yiling Lu

Annie N Y Cheung

Gordon B Mills

Lydia W T Cheung

Affiliations

Soon will be listed here.

Abstract

Copy number loss of PIK3R1 (p85α) most commonly occurs in ovarian cancer among all cancer types. Here we report that ovarian cancer cells manifest a spectrum of tumorigenic phenotypes upon knockdown of PIK3R1. PIK3R1 loss activates AKT and p110-independent JAK2/STAT3 signaling through inducing changes in the phosphorylation of the docking protein Gab2, thereby relieving the negative inhibition on AKT and promoting the assembly of JAK2/STAT3 signalosome, respectively. Additional mechanisms leading to AKT activation include enhanced p110α kinase activity and a decrease in PTEN level. PIK3R1 loss renders ovarian cancer cells vulnerable to inhibition of AKT or JAK2/STAT3. The combination of AKT and STAT3 inhibitors significantly increases the anti-tumor effect compared to single-agent treatments. Together, our findings provide a rationale for mechanism-based therapeutic approach that targets tumors with loss of PIK3R1.

Citing Articles

High Frequency of Alterations in Ovarian Cancers: Clinicopathological and Molecular Associations.

Rzepecka I, Tysarowski A, Konopka B, Dansonka-Mieszkowska A, Kupryjanczyk J Cancers (Basel). 2025; 17(2).

PMID: 39858051 PMC: 11764438. DOI: 10.3390/cancers17020269.

Herb pair of Huangqi-Danggui exerts anti-tumor immunity to breast cancer by upregulating PIK3R1.

Liu H, Lian L, Hou L, Liu C, Ren J, Qiao Y Animal Model Exp Med. 2024; 7(3):234-258.

PMID: 38863309 PMC: 11228089. DOI: 10.1002/ame2.12434.

Long non-coding RNA JPX promotes endometrial carcinoma progression via janus kinase 2/signal transducer and activator of transcription 3.

Xiong H, Zhang W, Xie M, Chen R, Chen H, Lin Q Front Oncol. 2024; 14:1340050.

PMID: 38784043 PMC: 11112342. DOI: 10.3389/fonc.2024.1340050.

Network Pharmacology and Molecular Docking Identify the Potential Mechanism and Therapeutic Role of in Alzheimer's Disease.

Peng Y, Zhou C Drug Des Devel Ther. 2024; 18:1199-1219.

PMID: 38645989 PMC: 11032720. DOI: 10.2147/DDDT.S450739.

Evaluating synergistic effects of metformin and simvastatin on ovarian cancer cells.

Mikhael S, Kurdi A, Khoueiry-Zgheib N, Tahtouh R, Nasr R, Hilal G PLoS One. 2024; 19(3):e0298127.

PMID: 38489280 PMC: 10942021. DOI: 10.1371/journal.pone.0298127.

References

Cheung L, Hennessy B, Li J, Yu S, Myers A, Djordjevic B . High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 2011; 1(2):170-85. PMC: 3187555. DOI: 10.1158/2159-8290.CD-11-0039. View

Jaiswal B, Janakiraman V, Kljavin N, Chaudhuri S, Stern H, Wang W . Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell. 2009; 16(6):463-74. PMC: 2804903. DOI: 10.1016/j.ccr.2009.10.016. View

Cizkova M, Vacher S, Meseure D, Trassard M, Susini A, Mlcuchova D . PIK3R1 underexpression is an independent prognostic marker in breast cancer. BMC Cancer. 2013; 13:545. PMC: 4225603. DOI: 10.1186/1471-2407-13-545. View

Chang R, Xiao S, Lei X, Yang H, Fang F, Yang L . miRNA-487a Promotes Proliferation and Metastasis in Hepatocellular Carcinoma. Clin Cancer Res. 2016; 23(10):2593-2604. DOI: 10.1158/1078-0432.CCR-16-0851. View

Chiu Y, Lee J, Cantley L . BRD7, a tumor suppressor, interacts with p85α and regulates PI3K activity. Mol Cell. 2014; 54(1):193-202. PMC: 4004185. DOI: 10.1016/j.molcel.2014.02.016. View

Saini U, Naidu S, ElNaggar A, Bid H, Wallbillich J, Bixel K . Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. Oncogene. 2016; 36(2):168-181. PMC: 5338638. DOI: 10.1038/onc.2016.197. View

Chou T . Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010; 70(2):440-6. DOI: 10.1158/0008-5472.CAN-09-1947. View

Kandoth C, McLellan M, Vandin F, Ye K, Niu B, Lu C . Mutational landscape and significance across 12 major cancer types. Nature. 2013; 502(7471):333-339. PMC: 3927368. DOI: 10.1038/nature12634. View

Gao J, Aksoy B, Dogrusoz U, Dresdner G, Gross B, Sumer S . Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6(269):pl1. PMC: 4160307. DOI: 10.1126/scisignal.2004088. View

10.

Thorpe L, Spangle J, Ohlson C, Cheng H, Roberts T, Cantley L . PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α. Proc Natl Acad Sci U S A. 2017; 114(27):7095-7100. PMC: 5502636. DOI: 10.1073/pnas.1704706114. View

11.

Ni S, Zhao C, Feng G, Paulson R, Correll P . A novel Stat3 binding motif in Gab2 mediates transformation of primary hematopoietic cells by the Stk/Ron receptor tyrosine kinase in response to Friend virus infection. Mol Cell Biol. 2007; 27(10):3708-15. PMC: 1899994. DOI: 10.1128/MCB.01838-06. View

12.

Cheung L, Walkiewicz K, Besong T, Guo H, Hawke D, Arold S . Regulation of the PI3K pathway through a p85α monomer-homodimer equilibrium. Elife. 2015; 4:e06866. PMC: 4518712. DOI: 10.7554/eLife.06866. View

13.

Hedvat M, Huszar D, Herrmann A, Gozgit J, Schroeder A, Sheehy A . The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009; 16(6):487-97. PMC: 2812011. DOI: 10.1016/j.ccr.2009.10.015. View

14.

Cheung L, Yu S, Zhang D, Li J, Ng P, Panupinthu N . Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors. Cancer Cell. 2014; 26(4):479-94. PMC: 4198486. DOI: 10.1016/j.ccell.2014.08.017. View

15.

Lin Y, Yang Z, Xu A, Dong P, Huang Y, Liu H . PIK3R1 negatively regulates the epithelial-mesenchymal transition and stem-like phenotype of renal cancer cells through the AKT/GSK3β/CTNNB1 signaling pathway. Sci Rep. 2015; 5:8997. PMC: 4355729. DOI: 10.1038/srep08997. View

16.

Hart J, Liao L, Yates 3rd J, Vogt P . Essential role of Stat3 in PI3K-induced oncogenic transformation. Proc Natl Acad Sci U S A. 2011; 108(32):13247-52. PMC: 3156164. DOI: 10.1073/pnas.1110486108. View

17.

McGlade C, Ellis C, Reedijk M, Anderson D, Mbamalu G, Reith A . SH2 domains of the p85 alpha subunit of phosphatidylinositol 3-kinase regulate binding to growth factor receptors. Mol Cell Biol. 1992; 12(3):991-7. PMC: 369531. DOI: 10.1128/mcb.12.3.991-997.1992. View

18.

Ren Z, Schaefer T . ErbB-2 activates Stat3 alpha in a Src- and JAK2-dependent manner. J Biol Chem. 2002; 277(41):38486-93. DOI: 10.1074/jbc.M112438200. View

19.

Rosen D, Mercado-Uribe I, Yang G, Bast Jr R, Amin H, Lai R . The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer. 2006; 107(11):2730-40. DOI: 10.1002/cncr.22293. View

20.

Yan L, Liu Y, Xiang J, Wu Q, Xu L, Luo X . PIK3R1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer. Int J Oncol. 2015; 48(2):471-84. PMC: 4725461. DOI: 10.3892/ijo.2015.3287. View